More and more consumers are expecting transparency from companies, and this Houston startup is on a mission to use blockchain to make businesses more transparent. Getty Images

More than two-thirds of the country's consumers have been reported saying that a business's social reputation will influence their buying decisions. A Houston blockchain startup has teamed up with another company to increase transparency.

Topl and Denver-based TrackX, a software-as-a-service asset management and supply chain solution provider, have entered into a partnership aimed at combining technology to create a verifiable tracking and tracing solution to equip company supply chains with sustainability, transparency, and efficiency.

According to Topl CEO, Kim Raath, the FDA announced new requirements in September, and the new rule requires full traceability in several agri-food products.

"This new rule will force many agri-food brands to take a deep look across their supply chains and find a way to track and trace their products," says Raath in a press release. "Topl and TrackX's solution will be a great option for these companies having to comply with new regulations and compliance mandates. Further, our joint solution allows users to visualize their supply chain data, monitor suppliers, and easily report the progress of ESG initiatives to all stakeholders."

Kim Raath is the CEO of Topl. Photo courtesy of Topl

Together with Topl's purpose-built blockchain technology and TrackX's core enterprise asset management and supply chain optimization capabilities, companies can securely share verified event data to lower costs and increase transparency.

"Our clients have a unique opportunity to turn supply chain optimization into a competitive advantage," says Tim Harvie, TrackX CEO, in the release. "TrackX already automates supply chain execution and analytics for many leading brands and retailers.

"Tight integration with Topl's blockchain will now provide the 'proof' to all supply chain stakeholders that certain events have occurred," he continues. "In partnership with Topl, our enterprise customers will have the tracing, tracking, visibility and accountability they need to meet their digital supply chain and ESG initiatives."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.